|
Jul 16
|
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
|
|
Jul 15
|
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Key Market Data
|
|
Jul 15
|
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch
|
|
Jul 15
|
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
|
|
Jul 15
|
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
|
|
Sep 30
|
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
|
|
Sep 26
|
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
|
|
Sep 25
|
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
|
|
Jul 29
|
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
|
|
Jul 28
|
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
|
Jul 11
|
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
|
Jun 21
|
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?
|
|
May 15
|
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 15
|
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
|
|
May 14
|
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
|
|
May 13
|
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 8
|
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
|
|
May 8
|
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
|
|
May 7
|
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
|
|
Apr 19
|
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
|